MDimune signs research agreement with Australian National University
Jae-Young Han
Dec 07, 2022 (Gmt+09:00)
MDimune, a South Korean biotech company, said on Wednesday that it had signed an agreement with the Clear Vision Research (CVR) Lab, a research group within the Australian National University, to jointly research and develop macular degeneration treatments.
MDimune is a company that possesses cell-derived vesicles(CDVs) production technology that can be used as a drug delivery system by extruding cells.
The CVR Lab is a group that intensively studies age-related macular degeneration within the university, and has conducted initial animal experiments to see whether the CDVs provided by MDimune can be used for the treatment of age-related macular degeneration.
With the latest joint research pact, MDimune and the CVR Lab plan to find out the therapeutic effect of CDVs.
MDimune expects this collaboration to facilitate the commercialization of drug delivery systems.